LOGIN  |  REGISTER
Terns Pharmaceuticals

Becton Dickinson Announces Webcast of Annual Meeting of Shareholders

January 05, 2024 | Last Trade: US$227.68 3.85 1.72

FRANKLIN LAKES, N.J., Jan. 5, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, January 23, 2024, at 1:00 p.m. (ET).

The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors and a replay will be available shortly after the call at the same website.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson

Contacts:

 
  

Media:

Investors:

Troy Kirkpatrick

Adam Reiffe

VP, Public Relations

Sr. Director, Investor Relations

858.617.2361

201.847.6927        

This email address is being protected from spambots. You need JavaScript enabled to view it.         

This email address is being protected from spambots. You need JavaScript enabled to view it.     

Terns Pharmaceuticals

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB